Michelena X, Zhao SS, Dubash S, et al. - This study was sought to present the baseline characteristics, bDMARD response, and drug survival of ankylosing spondylitis (axSpA) patients in the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis (BSRBR-AS) according to radiographic status. Researchers conducted a national prospective cohort including axSpA participants classified according to the ASAS criteria. They compared baseline data of patients starting bDMARDs. Treatment response was evaluated by using Ankylosing Spondylitis Disease Activity Scores for low disease status, clinically important improvement, and major improvement at one year. They performed Cox proportional hazard analysis after adjusting for clinically relevant cofounders. A total of 1,145 axSpA patients were included in the study. The level of biologic response and drug survival was comparable between nr-axSpA and r-axSpA, although there seemed to be some differences in the baseline characteristics when exploring this cohort according to the radiographic status which is likely related to the natural history of the disease.